Press Releases and Adhoc Announcements 2022/2021

Friday, 09 September 2022 17:46

AH: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate

Tuesday, 30 August 2022 17:46

PR: Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure

Friday, 12 August 2022 12:27

PR: Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million

Wednesday, 13 July 2022 10:03

AH: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate

Tuesday, 12 July 2022 07:13

PR: Heidelberg Pharma Reports on First Half-Year 2022

Tuesday, 28 June 2022 13:53

PR: Heidelberg Pharma Reports Outcome of the Annual General Meeting 2022

Monday, 09 May 2022 16:34

AH: Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure

Thursday, 28 April 2022 07:16

PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022

Thursday, 07 April 2022 14:33

PR: Heidelberg Pharma to Present New Data on its Proprietary ATAC® Technology Platform at the AACR Annual Meeting 2022

Thursday, 24 March 2022 07:30

PR: Heidelberg Pharma Announces Financial Figures for Fiscal Year 2021 and Provides Business Update

Thursday, 10 March 2022 07:59

PR: Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117

Monday, 28 February 2022 07:07

PR: Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment

Sunday, 27 February 2022 13:16

AH: Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment

Thursday, 17 February 2022 12:37

AH: Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini

Tuesday, 15 February 2022 07:12

PR: Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma

Thursday, 28 October 2021 12:53

PR: Heidelberg Pharma Participates at Various Conferences

Thursday, 07 October 2021 07:10

PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2021

Friday, 01 October 2021 14:30

PR: Heidelberg Pharma AG Announces Adjustment of Guidance

Thursday, 09 September 2021 14:52

PR: Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences

Tuesday, 07 September 2021 07:29

PR: Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US

Monday, 19 July 2021 16:21

PR: Paul Ehrlich Institute Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101

Thursday, 08 July 2021 07:22

PR:  Heidelberg Pharma Reports on First Half-Year 2021

Thursday, 17 June 2021 09:40

PR: Heidelberg Pharma Announces Participation at Various Conferences

Tuesday, 15 June 2021 22:30

Heidelberg Pharma AG Raises EUR 20 Million From Private Placement

Tuesday, 15 June 2021 18:30

AH: Heidelberg Pharma AG to Raise Capital in a Private Placement

Tuesday, 18 May 2021 14:38

PM: Annual General Meeting 2021 of Heidelberg Pharma Approves All Proposed Resolutions

Thursday, 29 April 2021 07:22

PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2021

Wednesday, 31 March 2021 08:14

PR: Heidelberg Pharma to Present New Data on its Proprietary ATAC Technology Platform at the AACR Annual Meeting 2021

Thursday, 25 March 2021 07:18

PR: Heidelberg Pharma announces financial figures for fiscal year 2020 and provides business update

Friday, 19 March 2021 19:24

AH: Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini

Monday, 01 March 2021 07:26

PR: Heidelberg Pharma Expands Management Team

Thursday, 11 February 2021 08:04

PR: Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine

Thursday, 04 February 2021 10:58

AH: FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.